Nonmotor outcomes in Parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy?
Nonmotor symptoms are an integral part of Parkinson’s disease and cause significant morbidity. Pharmacological therapy helps alleviate the disease but produces nonmotor manifestations. While deep brain stimulation (DBS) has emerged as the treatment of choice for motor dysfunction, the effect on nonm...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2012-01-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/1756285611423412 |
id |
doaj-6b833e27e1a24b8aa4ae72ebdada2e6a |
---|---|
record_format |
Article |
spelling |
doaj-6b833e27e1a24b8aa4ae72ebdada2e6a2020-11-25T02:59:17ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28561756-28642012-01-01510.1177/1756285611423412Nonmotor outcomes in Parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy?Rupam BorgohainRukmini Mridula KandadaiAfshan JabeenMeena A. KannikannanNonmotor symptoms are an integral part of Parkinson’s disease and cause significant morbidity. Pharmacological therapy helps alleviate the disease but produces nonmotor manifestations. While deep brain stimulation (DBS) has emerged as the treatment of choice for motor dysfunction, the effect on nonmotor symptoms is not well known. Compared with pharmacological therapy, bilateral subthalamic nucleus (STN)-DBS or globus pallidum interna (GPi)-DBS has significant beneficial effects on pain, sleep, gastrointestinal and urological symptoms. STN-DBS is associated with a mild worsening in verbal fluency while GPi-DBS has no effect on cognition. STN-DBS may improve cardiovascular autonomic disturbances by reducing the dose of dopaminergic drugs. Because the motor effects of STN-DBS and GPi-DBS appear to be similar, nonmotor symptoms may determine the target choice in surgery of future patients.https://doi.org/10.1177/1756285611423412 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Rupam Borgohain Rukmini Mridula Kandadai Afshan Jabeen Meena A. Kannikannan |
spellingShingle |
Rupam Borgohain Rukmini Mridula Kandadai Afshan Jabeen Meena A. Kannikannan Nonmotor outcomes in Parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy? Therapeutic Advances in Neurological Disorders |
author_facet |
Rupam Borgohain Rukmini Mridula Kandadai Afshan Jabeen Meena A. Kannikannan |
author_sort |
Rupam Borgohain |
title |
Nonmotor outcomes in Parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy? |
title_short |
Nonmotor outcomes in Parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy? |
title_full |
Nonmotor outcomes in Parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy? |
title_fullStr |
Nonmotor outcomes in Parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy? |
title_full_unstemmed |
Nonmotor outcomes in Parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy? |
title_sort |
nonmotor outcomes in parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy? |
publisher |
SAGE Publishing |
series |
Therapeutic Advances in Neurological Disorders |
issn |
1756-2856 1756-2864 |
publishDate |
2012-01-01 |
description |
Nonmotor symptoms are an integral part of Parkinson’s disease and cause significant morbidity. Pharmacological therapy helps alleviate the disease but produces nonmotor manifestations. While deep brain stimulation (DBS) has emerged as the treatment of choice for motor dysfunction, the effect on nonmotor symptoms is not well known. Compared with pharmacological therapy, bilateral subthalamic nucleus (STN)-DBS or globus pallidum interna (GPi)-DBS has significant beneficial effects on pain, sleep, gastrointestinal and urological symptoms. STN-DBS is associated with a mild worsening in verbal fluency while GPi-DBS has no effect on cognition. STN-DBS may improve cardiovascular autonomic disturbances by reducing the dose of dopaminergic drugs. Because the motor effects of STN-DBS and GPi-DBS appear to be similar, nonmotor symptoms may determine the target choice in surgery of future patients. |
url |
https://doi.org/10.1177/1756285611423412 |
work_keys_str_mv |
AT rupamborgohain nonmotoroutcomesinparkinsonsdiseaseisdeepbrainstimulationbetterthandopaminereplacementtherapy AT rukminimridulakandadai nonmotoroutcomesinparkinsonsdiseaseisdeepbrainstimulationbetterthandopaminereplacementtherapy AT afshanjabeen nonmotoroutcomesinparkinsonsdiseaseisdeepbrainstimulationbetterthandopaminereplacementtherapy AT meenaakannikannan nonmotoroutcomesinparkinsonsdiseaseisdeepbrainstimulationbetterthandopaminereplacementtherapy |
_version_ |
1724703274704044032 |